Our Platform

Stem Cells

We are developing our business in cell therapeutics and capitalizing on the increasing importance and promise that adult stem cells have in regenerative medicine, particularly applied to orthopedics.

scroll
Stem Cell Therapy Pipeline
AlloJoin® Therapy for Knee Osteoarthritis
Re-Join® Therapy for Knee Osteoarthritis

Stem Cell Therapy Pipeline

We are developing our business in cell therapeutics and capitalizing on the increasing importance and promise that adult stem cells have in regenerative medicine. Our most advanced candidate involves adipose-derived mesenchymal stem cells to treat KOA.

Adult mesenchymal stem cells can currently be isolated from a variety of adult human sources, such as liver, bone marrow, and adipose (fat) tissue. The advantages in using adipose tissue (as opposed to bone marrow or blood) are that it is one of the richest sources of pluripotent cells in the body, the easy and repeatable access to fat via liposuction, and the simple cell isolation procedures that can begin to take place even on-site with minor equipment needs.

haMPC

technology indication preclinical phase I phase II phase III
AlloJoin® (Allogeneic) KOA

Re-Join® (Autologous) KOA


AlloJoin® Therapy for Knee Osteoarthritis

Approved for Phase II Clinical Trial

January 2019: AlloJoin® Therapy becomes the 1st Stem Cell Drug Application approved in China for Phase II clinical trials VIEW ANNOUNCEMENT

AlloJoin® therapy is built on our promising technology platform and clinical experience using autologous adipose-derived mesenchymal progenitor cells (haMPC) Re-Join® therapy for the treatment of KOA. The development of an allogeneic product seeks to provide additional benefits to patients and physicians in that it generates a bank of third-party donor haMPCs that can be used for off-the-shelf treatment, allowing for ease of manufacture and use, lower costs and a selection of more healthy donors. This could increase the number of patients that can be treated by a single isolation with the same quality manufacturing procedures.

Re-Join® Therapy for Knee Osteoarthritis

The China NMPA (formerly CFDA) has accepted the Company’s IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA

Our Re-Join® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for KOA is an interventional therapy that consists of adipose (fat) tissue obtained from the patient, and are then expanded using CBMG’s proprietary culture medium (serum-free and antibiotics-free), and formulated for Re-Join® therapy using CBMG’s proprietary formulation.